Study S001873

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05822609
Acronym: RT1D
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 60
Start: 2024-04-05
Primary completion: 2027-06
Lead sponsor: University of Washington
Conditions: Diabetic Kidney Disease; Type 1 Diabetes
Interventions: DRUG:Semaglutide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change in urine albumin excretion [Baseline to 26 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0029633	Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease. Kugathasan L, Expert review of clinical immunology	2025	Narrative review	PMID 40693871 DOI	cites ClinicalTrials.gov:NCT05822609; registry reference DERIVED:40693871